Purpose To evaluate the role of cytochrome 450 2D6 (CYP2D6) and ABCB1 variants on plasma risperidone concentrations and treatment response in 83 drug-naive patients experiencing a first episode of psychosis. Methods All patients were treated with risperidone for 8 weeks. The CYP2D6 genotyping was performed by allelespecific PCR-restriction fragment length polymorphism analysis (for alleles *3,*4,*6) and long-distance PCR (for duplications and allele *5), while real-time PCR analysis was used for the ABCB1 G2677T/A and C3435T variants. Plasma concentrations of risperidone and 9-OH risperidone were measured by high-performance liquid chromatography. Results The number of patients with the CYP2D6 wild type (wt)/wt, wt/mutation (mut) and mut/mut genotype was 43, 32 and 8, respectively. The number of patients with the ABCB1 2677G/G, G/T and T/T variants was 29, 42 and 12, respectively; those with the 3435CC, C/T and T/T variants was 25, 37 and 21, respectively. The CYP2D6 genotype had a strong effect on the steady-state dose-corrected plasma levels (C/D) of risperidone, its 9-OH metabolite and the active moiety, while the ABCB1 2677 T/T and 3435 T/T genotypes has similarly strong effects on the active moiety C/D. The CYP2D6 poor metabolizers had a significantly higher risperidone C/D and active moiety C/D and lower 9-OH risperidone C/D. The ABCB1 3435 T allele and the ABCB1 2667 T-3435 T haplotype carriers were more frequent among subjects without extrapyramidal syndromes. Patients showed significant improvements in positive and general symptoms, but not in negative symptoms. These changes were not related to variations in genetic and drug concentration data. Conclusion Our findings suggest that CYP2D6 and ABCB1 G2677T and C3435T may be useful determinants of risperidone plasma concentrations, but the clinical implications of these associations in relation to treatment response and side-effects remain unclear.
Introduction
Everyday clinical experience suggests that patients with schizophrenia significantly vary in their response to antipsychotic treatment. Those patients experiencing their first episode of psychosis fall into the same category. However, disregarding the confounding effects of illness chronicity and previous antipsychotic treatments, their variability in treatment response could be significantly related to drug metabolic polymorphisms [1] .
Risperidone is a widely used antipsychotic drug with potent antagonistic properties for the dopamine D2 and serotonin 5-HT2 receptors. Its active metabolite, 9-hydroxyrisperidone (9-OH-risperidone), is approximately equipotent with the parent drug in terms of dopamine receptor affinity. Therefore, the entire active moiety (risperidone + 9-OH-risperidone) is considered to contribute to the full antipsychotic effect [2] . According to in vivo and in vitro studies, cytochrome 450 2D6 (CYP2D6) is responsible for the metabolism of risperidone [3, 4] , and it has been suggested that several mutated alleles of the CYP2D6 gene may cause eliminate its activity entirely (e.g. CYP2D6*3, CYP2D6*4, CYP2D6*5) or increase its activity (CYP2D6*2xN) [5] . Risperidone has strong affinity for P-glycoprotein (P-gp), a transporter that regulates drug bioavailability by controlling intestinal drug absorption, renal excretion and transport across the blood-brain barrier [6] . P-gp is a member of the adenosine triphosphate-binding cassette (ABC) superfamily, and the ABCB1 gene encodes its expression [7] . Two single-nucleotide polymorphisms (SNPs), namely, exon 21 (G2677T/A) and the missense polymorphism within exon 21 (rs2032582) , and the silent mutation C3435T in exon 26 (rs1045642) are associated with a lower level of intestinal ABCB1 expression [8] .
Since certain cytochrome enzyme CYP2D6 and ABCB1 variants have different functional capacities, genotyping may be a clinically useful tool for individualizing antipsychotic therapy, mainly in terms of dose optimization and the prevention of adverse effects. It has been shown that CYP2D6 genotypes have a significant effect on the steadystate plasma levels of risperidone and 9-OH risperidone [9] , but that the effect of ABCB1 variants can vary from moderate [10] to completely absent [11] . We report here the first study to search for these effects in drug-naïve patients experiencing their first episode of psychosis. Our aim was to evaluate the role of CYP2D6 and ABCB1 variants in therapeutic efficacy and safety after 8 weeks of treatment with orally administered risperidone.
Methods

Subjects
The study included 83 subsequently hospitalized patients who met the following criteria: (1) an ICD-10 diagnosis of firstepisode schizophrenia spectrum disorder [12] ; (2) drug-naïve status in terms of using antipsychotics; (3) initiation of risperidone treatment based on the standard clinical practice. All patients were treated with orally administered risperidone and followed-up for 8 weeks. No other psychotropic medication was prescribed, with the exception of anticholinergics (biperiden) for the alleviation of extrapyramidal symptoms (44 patients, mean dose 2.74 mg±1.6) and benzodiazepines (diazepam) as hypnotics (37 patients, mean dose 7.21 mg±3.09). The sample was predominantly female (n=66, 79.5%), and the average age was 30.29±8.1 years.
The majority were smokers (n=45, 54.2%), single (n=45, 54.2%) and with a high school education (n=63, 75.9%). Approximately one-third of the patients had a case of psychosis in their family (n=25, 30.1%). Mean body weight was 74.26±11.49 kg. The clinical and demographic data for these patients are given in Table 1 .
All participants were of Croatian origin. Of the 101 patients initially invited to participate in the study, six refused to be included and three were excluded from the final analyses due to incomplete follow-up data. In seven cases, the patient's condition became significantly worse several days before the study end-point, and clinicians were forced to increase the drug's dose (n=4) or switch to another antipsychotic (olanzapine, n=2 and fluphenazine, n=1), thus disabling the measurement of the drug's concentration at the end-point. In order to stick to the original study design as much as possible, we took the decision to exclude these patients from further analysis. Two additional subjects were excluded because their risperidone and 9-OH risperidone concentrations were lower than level of detection. Even though all participants were inpatients and drugs were given under the supervision of hospital nurses, it may have been possible that they were not using the drug at all. The study was performed at the University Hospital Centre Zagreb, Department of Psychiatry, from 2006 to 2009 as part of the project "Effects of pharmacogenetic variants on pathogenesis of schizophrenia and treatment response". The study protocol was approved by the Institutional Ethical Committee, and all participants gave written informed consents.
Clinical assessment
Baseline clinical assessment consisted of a structured psychiatric interview, collection of socio-demographic data, assessment of the severity of the psychopathology (using the Positive and Negative Syndrome Scale, PANSS) [13] , tobacco use, physical examination and body weight measurements. PANSS was rated by two trained raters (V.M. and N.J.), and the inter-rater reliability was 0.76. Both raters were blind to the genotype and plasma concentration data. The SimpsonAngus scale was used to evaluate extrapyramidal symptoms (EPS), and patients with score ≥3 were classified as the EPS+ group [14] . Patients were also assessed for other side effects, such as amenorrhea, galactorrhea and gynecomastia.
Genotyping
The CYP2D6 genotype of all patients was determined. An allele-specific PCR-restriction fragment length polymorphism (RFLP) analysis was used for identifying the CYP2D6*3,*4 and *6 alleles, and long-distance PCR was used for identifying CYP2D6* duplication and the CYP2D6*5 alleles. All PCR analyses were performed in an Applied Biosystems Thermo Cycler 9700 [15] . For the ABCB1 2677G > T/A, and 3435C > T variant, a real-time PCR method was used in a LightCycler system (Roche Applied Sciences, Indianapolis, IN) with the Fast Start DNA Master plus HybProbe Master Mix [16] [17] [18] .
Plasma concentrations
Samples were collected after 8 weeks of treatment and after a stable dose of the drug had been achieved for a minimum of 15 days. The dosage of risperidone was completely left up to a clinician's decision, based on the rules of good clinical practice. Blood samples were obtained in the morning (0700 hours), 12 h after the bedtime dose and before the morning dose. Plasma concentrations of risperidone and 9-hydroxyrisperidone (TRC, North York, ON, Canada) were measured by a high-performance liquid chromatography (HPLC) method with diode array detector (Shimadzu, Kyoto, Japan) [19] . Compounds are separated using a linear gradient on a Waters Symmetry C18 column (Waters, Milford, MA). Solvent A was acetonitrile and solvent B consisted of 0.05 M NaH 2 PO 4 · H 2 O, pH 3.8.
The gradient ratio of solvent B started at 25%, increasing to 60% during the 25-min period of the analysis. The flow rate was 1.5 mL min −1 , and the oven was set at 45°C. The eluted substance was detected at 200 nm (fluoxetine as internal standard) and 277 nm (risperidone and 9-OH risperidone), respectively. All compounds were confirmed with standard UV spectra at 190-370 nm. One milliliter of plasma was mixed with 50 μL of the aqueous internal standard solution and 100 μL of 0.5 M NaOH. The mixture was vortexed for 3 s, then 5 mL of extraction solvent was added (hexane-ethyl acetate 1:1); the mixture was then shaken and centrifugated. Four milliliters of the organic layer was evaporated to dryness at 37°C, and the residue was dissolved in 150 μL of mobile phase. The method was validated for the concentration range 12-244 nmol L −1 for risperidone and 12-234 nmol L −1 for 9-OH risperidone; the limit of detection was 6.1 and 5.8 nmol L −1 for these analytes respectively. Accuracy at three concentrations ranged from 94.3 to 103.6%. Inter-and intra-day relative standard deviations (SD) were lower than 12%. These analytes are included in the external quality control scheme (UK NEQAS).
Statistical analysis
All statistical analyses central to the aim of this study were performed with the following genotype groups: CYP2D6 wild type/wild type (wt/wt), wt/mutation (mut) and mut/mut, ABCB1 2677G/G, G/T, T/T and ABCB1 3435C/C, C/T, T/T. ABCB12677 alleles G and T, and ABCB1 3435 alleles C and T were analysed separately in a logistic regression model described in detail below. Haplotype analysis was performed on the C3435T and G2677T variants on the basis of linkage disequilibrium observed between both positions. Steady-state plasma concentrations of risperidone and 9-OH-risperidone were adjusted by drug dosage (dose-corrected values) and presented as geometric means and 95% confidence intervals (95% CI). When referred to, the active moiety concentration stands for the sum of risperidone and 9-OH-risperidone concentrations. Differences in dose-corrected plasma drug concentrations (C/Ds) between different genotypes were analysed using the Kruskal-Wallis test with the MannWhitney test for post hoc comparisons. Due to multiple comparisons, the level of statistical significance for the Mann-Whitney test was lowered to p<0.017 (0.05/3=0.017). Interval measures are presented as the means with SD. Chisquare tests were used to compare the groups for different categorical variables. Differences in psychopathology (measured by PANSS) were examined using the one-way analysis of variance (ANOVA; all results were statistically nonsignificant) and the paired sample t test. A binary logistic regression model was created to identify which genetic variant best predicted the patient's clinical response to treatment. The latter was dichotomized depending on whether the individual value was below or above 50% improvement in total PANSS score and used as a dependent variable in the model. Independent variables were: age, gender, CYP2D6, ABCB1 G2677T and ABCB1 C3435T genotypes (each as wt/wt, wt/mut and mut/mut), ABCB12677 alleles (G and T) and ABCB1 3435 alleles © and T). The Statistical Package for the Social Sciences (SPSS, Chicago, IL) ver. 12 was used for all of the above-mentioned analyses.
Results
Distribution of the CYP2D6 and ABCB1 genotype
The number of patients with the CYP2D6 wt/wt, wt/mut and mut/mut genotype was 43, 32 and 8, respectively. Only one patient carried more than two copies of a functional CYP2D6 allele (ultrarapid metabolizer) and was subsequently excluded from the final analysis. The risperidone and 9-OH risperidone concentration of this patient was 0 and 56 nmol L −1 , respectively, which is in agreement with the ultraextensive metabolic phenotype. The number of patients with the ABCB1 2677G/G, 2677G/T and 2677T/T genotype was 29, 42 and 12, respectively. None of the participants carried a 2677A allele. Furthermore, a total of 25 patients were ABCB1 3435C/C carriers, while 37 and 21 patients carried the 3435C/T and 3435T/T variants ( Table 2 ). The two SNPs were in linkage disequlibrium (D′=0.78), and the most frequent ABCB1 haplotype was 2677G-3435C (0.318), followed by the 2677T-3435T (0.265), the 2677G-3435T (0.238) and the 2677T-3435C (0.179). There were no differences between these genotype subgroups in terms of the studied sociodemographic or clinical variables, including PANSS scores at baseline and end-point.
The steady-state plasma concentrations
The drug was prescribed at the mean dose of 3.96± 1.5 mg (range 1-8 mg). The schemes were as follows: "8 mg/day" (n=3), "7 mg/day" (n=1), "6 mg/day" (n=7), "5 mg/day" (n=4), "4 mg/day" (n=30), "3 mg/day" (n= 22), "2 mg/day" (n=15) and "1 mg/day" (n=1). The C/Ds of risperidone, 9-OH risperidone and the active moiety are given in Table 2 . In general, the CYP2D6 genotype had a statistically significant effect on the risperidone C/D Table 2 The difference in dose-corrected plasma concentrations (C/D) of risperidone, 9-OH-risperidone, the active moiety and risperidone/9-OH risperidone ratio between the CYP2D6 and ABCB1 C3435T and G2677T/A genotypes Genotype Total sample, Data are shown as geometric means, with the 95% confidence interval (CI) in parenthesis. Data were treated using the Kruskal-Wallis tst (intragroup comparisons described in the text)
9-OH-risperidone, 9-hydroxyrisperidone; active moiety, sum of risperidone + 9-OH risperidone; wt, wild type; mut, mutation (Kruskal-Wallis test 16.161, df=2, p<0.001), 9-OH risperidone C/D (9.699, df=2, p=0.008) and active moiety C/D (9.142, df=2, p=0.01). The ABCB1 G2677TA genotypes had a significant effect only on the active moiety C/D (KruskalWallis test 13.478, df=2, p=0.001). The ABCB1 C3435T genotypes had a statistically significant effect on the risperidone C/D (6.351, df=2, p=0.042) and active moiety C/D (14.744, df=2, p=0.001).
The role of the CYP2D6 poor metabolizers A total of eight patients were genotyped as CYP2D6 poor metabolizers (PMs; genotype CYP2D6 mut/mut). These patients had significantly higher risperidone C/D than homozygous extensive metabolizers (EMs; genotype CYP2D6 wt/wt; Mann Whitney U=1.00, Z=−3.83, p< 0.001) and heterozygous EMs (genotype CYP2D6 wt/mut; U = 8.00, Z = −3.38, p < 0.001). The same pattern was observed for the active moiety C/D-the PMs had significantly higher active moiety C/D than homozygous EMs (U=30.00, Z=−2.73, p=0.004) and heterozygous EMs (U=34.00, Z=−2.12, p=0.033). However, PMs had a significantly lower 9-OH risperidone C/D than homozygous EMs (U=49.000, Z=−2.03, p=0.045) or heterozygous EMs (U=21.000, Z=−2.8, p=0.004). The risperidone/9-OH risperidone ratio was >1 in PMs, thereby indicating a lack of CYP2D6 activity. The same ratio was higher in PMs than in homozygous EMs (U=0.00, Z=−3.864, p<0.001) or heterozygous EMs (U =6.00, Z=−3.457, p<0.001). Please see Fig. 1 and Table 2 .
The role of ABCB1 genotypes on differences in drug concentrations
The ABCB1 2677 T/T genotype was associated with higher levels of the dose-corrected active moiety than the ABCB1 2677G/G genotype (Mann Whitney U=25.00, Z=−3.151, p=0.001) and the ABCB1 2677G/T genotype (MannWhitney U=30.00, Z=−3.356, p<0.001). The ABCB1 3435 T/T genotype was associated with a higher of risperdone C/D than the 3435C/C genotype (MannWhitney U=73.00, Z=−2.529, p=0.011). Similarly, the carriers of the 3435 T/T genotype had a higher active moiety C/D than those carrying the 3435C/C genotype (MannWhitney U=43.00, Z=−3.508, p<0.001) or the 3435C/T genotype (Mann-Whitney U=88.00, Z=−2.830, p=0.004).
The clinical response
No statistically significant difference in the PANSS was found when the genotype groups were compared for baseline and end-point (after 8 weeks of treatment) (Table 3) . Likewise, no statistically significant correlations were found between the PANSS scores and plasma concentrations (p>0.05). However, the majority of the patients did show a decrease in symptom severity. In comparison to baseline, the greatest benefits were seen in the reduced scores on the positive symptoms subscale (t test: t=14.356, df=82, p<0.001), general psychopathology subscale (t=10.558, p<0.001) and total PANSS score (t=10.181, p<0.001), but the difference was not significant for the negative symptoms score (t=1.6, p=0.114). Our next step was to search for the predictive value of the genotypes analysed (CYP2D6 wt/wt, wt/mut, mut/mut, ABCB1 C3435T and G2677T/A) and the ABCB1 alleles (ABCB1 3435 G and T, ABCB1 2677 C and T) on the clinical response (defined as 50% improvement from baseline in total PANSS). Based on these criteria, a total of 21 participants (25.3%) were responders. In terms of other serious side-effects, 11 women reported amenorrhea (13.3%), three suffered from galactorrhea (3.6%) and one had gynecomastia (1.2%). Two patients had EPSs of amenorrhea and galactorrhea concurrently.
Discussion
Our results suggest that the CYP2D6 genotype has a significant influence on the steady-state dose-corrected levels of risperidone, 9-OH risperidone and the active moiety, which is in accordance with the results from a number of earlier studies conducted on Italian [10] , Japanese [11] and Korean [20] subjects with schizophrenia. This is the first time that these results have been replicated on a Croatian (Slavic) population.
Of all the CYP2D6 phenotypes, PMs are of the highest significance for clinicians because this group is at risk for adverse reactions to medications and may reach toxic levels of medications at relatively low clinical doses. As expected, the PMs in our study were characterized by significantly higher levels of steady state dose-corrected risperidone and lower levels of dose-corrected 9-OH risperidone. In addition, the CYP2D6 PM phenotype was associated with a risperidone/9-OH risperidone ratio >1, which indicates the lack of CYP2D6 activity. What we also found was that the frequency of PMs in our sample was 9.6% which is threefold higher than that of the general population in Croatia (3%), while the frequencies of other two CYP2D6 genotypes did not differ much from the general population data [21] . This was a surprising and difficult to explain finding, especially since our patient group comprised patients experiencing their first episode of psychosis; as such, they were not treatment resistant nor had they experienced a high level of adverse effects. We did not find that they have significantly more side effects or different treatment response than others, but our results should be interpreted with caution due to small number of subjects. A study on a much larger sample of 325 persons stabilized on risperidone therapy found that the CYP2D6 PM phenotype triples the risk for moderate-to-marked adverse drug reactions and drug discontinuation. [22] .
With respect to the ABCB1 genotypes, the strongest effect was seen between the ABCB1 2677 T/T and ABCB1 3435 T/T genotypes and increased level of risperidone active moiety C/D. The 3435 T/T genotype may reduce the expression and Fig. 1 Boxplots illustrate dose-corrected plasma concentrations of risperidone (a), 9-hydroxyrisperidone (9-OH risperidone; b), active moiety (risperidone + 9-hydroxyrisperidone; c) and risperidone/9-OH risperidone ratio (d) among poor metabolizers (PMs, n=8) and homozygous (n=43) and heterozygous extensive metabolizers (EMs) (n=32). Bold black line Median value, box values between 25th and 75th quartile, whiskers extreme values of the distribution. The differences between the PMs and the EMs were analysed using a Mann-Whitney test. The PMs have significantly a higher risperidone dose-corrected plasma level (C/D) (a) than homozygous and heterozygous EMs (p<0.001 for both), a higher active moiety C/D (c) than homozygous EMs (p=0.004) and heterozygous EMs (p=0.033) and a higher risperidone/9-OH risperidone ratio (D, p<0.001 for both). The PMs have a lower 9-OH risperidone C/D (b) than homozygous EMs (p=0.045) or heterozygous EMs (p=0.004). CYP2D6 Cytochrome 450 2D6 activity of P-gp, thus limiting intestinal drug absorption and central nervous system penetration [8, 23] . We observed that half of our subjects had EPSs. However, the other half of our patients (EPS group) were characterized as by a significantly higher number of ABCB1 3435 T allele and ABCB1 2667 T-3435 T haplotype carriers. There was no difference in plasma levels with respect to these features. This finding suggests that ABCB1 3435 T allele and/or ABCB1 2667 T-3435 T haplotype variants may not be such strong mediators of the drug's penetration into the central nervous system after all. Even though two other studies have reported that higher plasma concentrations of the active moiety tend to be associated with a higher rate of extrapyramidal symptoms [24, 25] , it may be hard to establish a straightforward and firm association between the drug's levels peripherally and centrally. Since 9-OH risperidone has been marketed as a separate antipsychotic (paliperidone), we discuss our findings on 9-OH risperidone in more detail here. In an attempt to combine our results and the effects of the CYP2D6 and ABCB12677T/T and 3435 T/T genotypes, we can say that the level of the dose-corrected 9-OH risperidone was significantly lower in CYP2D6 PMs, while ABCB1 genotype had no effect on this metabolite. Therefore, we suggest that there are no additive effects between these genetic variants and that determination of these ABCB1 genotypes has very little clinical importance in terms of the individualization of paliperidone treatment. However, these findings need to be replicated since two other studies on Caucasian men reported that ABCB1 2677 T/T carriers had significantly lower 9-OH risperidone levels [10, 26] .
We found no clear association between the genotype and differences in plasma concentration and treatment response to [27] . Interestingly, in our previous study, we did find positive associations between the ABCB1 2677 T allele and 2677 T/T genotype and better treatment response in female patients with schizophrenia who were treated with another atypical antipsychotic-olanzapine [28] . In the study reported here, we found that after 8 weeks of risperidone treatment, a quarter of our patients had a 50% lower level of symptom severity (responders). There were significantly fewer people with EPSs among this group. Significant improvements were observed in positive and general symptoms, but not in negative symptoms. This finding is probably more contributable to the fact that risperidone may not be very efficient in reducing negative symptoms rather than to the not so high level of negative symptoms early in the course of schizophrenia in our patients. Secondly, this finding is of significance to clinicians working with this group of patients, especially because it has been shown that early non-response (as early as 1 or 2 weeks) can reliably predict subsequent nonresponse to treatment of schizophrenia [29, 30] .
The main limitation to this study is its relatively small sample size. It may be necessary to analyse much larger samples to show clear effects of drug metabolic polymorphisms on clinical outcome. However, the strengths of the study are related to the sample type (drug-naive patients) and naturalistic design (hopefully this might help clinicians in translating these results into the reality of their clinical practice).
In conclusion, our findings suggest that the CYP2D6 genotype has a strong effect on steady-state dose-corrected plasma levels of risperidone, its 9-OH metabolite and the active moiety, while the ABCB1 2677 T/T and 3435 T/T genotypes have similarly strong effects on the active moiety only. Additionally, the ABCB1 3435 T/T genotype has a somewhat weaker influence on risperidone C/D. The clinically significant group of CYP2D6 PMs were characterized with significantly higher levels of dose-corrected risperidone and active moiety, and lower levels of dosecorrected 9-OH risperidone. Those with extrapyramidal syndrome did not differ in drug plasma concentrations. However, the ABCB1 3435 T allele and the ABCB1 2667 T-3435 T haplotype carriers were more frequently present among subjects without extrapyramidal syndrome. Even though patients did show significant improvements in positive and general symptoms-but not in negative symptoms-these changes were not related to variations in genetic and drug concentration data. Therefore, our findings suggest that CYP2D6 and ABCB1 G2677T and C3435T may be useful determinants of risperidone plasma concentrations, but the clinical implications of these findings in relation to treatment response and side effects remain unclear.
